| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_36002650e924d3edaec88b4324ca7e83 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-737
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-731
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-731 |
| filingDate |
2015-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed00dca262025966d465c0b22ce84dbe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b7af54cf8d4fad8e32b5b33131714ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e6103e1052e5b563698c6fd51f9f5ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef206e30c95b66bcb9b38452a5311a64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9a4c2f53948467172ad37a3fadf697b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd35f58d9f92c566012eee75c1ba42b0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d972f8fdf42ab9ce2a48aa3dc120e84c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e777a02b626dda4038016b44cf5d80ec |
| publicationDate |
2015-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2015110430-A1 |
| titleOfInvention |
Ophthalmic compositions comprising iota-carrageenan |
| abstract |
The present invention relates to a pharmaceutical composition useful in the prophylactic or therapeutic topical treatment of viral eye infections caused by adenovirus of subtype D or influenza A virus of subtype H7. The composition in its ready-for-use formulation comprises iota carrageenan as an active antiviral ingredient and is essentially free of a metal halide salt or contains no more than 0.5% w/v of a metal halide salt. |
| priorityDate |
2014-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |